Forum Discussion
🔔 Update on access to Zoladex treatment
We heard your concerns about AstraZeneca's decision to discontinue Zoladex 3.6mg from 1 November 2026 - and we went to work on your behalf.
After coordinating advocacy with clinicians, consumers and key stakeholders, we're pleased to share that options will be available for those affected, including a free access program for eligible patients and work underway on alternative treatment pathways.
Supply continues in the meantime and we'll keep you informed every step of the way.
Full details available through the link in our bio. If you need support, our Helpline is here for you on
👉 Reach out to the BCNA Helpline 1800 500 258 for information and support
Read more here:
🔗 https://www.bcna.org.au/latest-news/bcna-news/update-on-access-to-zoladex-treatment
8 Replies
📢📢📢 A significant step forward for women who rely on monthly ovarian suppression treatment. 💗
Following months of uncertainty after the decision to remove Zoladex 3.6mg from the PBS on 1 November, PBAC has now recommended triptorelin (Diphereline) 3.75mg for PBS listing for breast cancer.
For women and their treating teams, this brings us one step closer to a sustainable, subsidised monthly treatment option.
It is also a powerful example of what can happen when women’s experiences are heard directly in decision-making.
Women told us about the anxiety, treatment uncertainty and difficult decisions they were facing. Clinicians advocated strongly for their patients. Government recognised the urgency, PBAC prioritised consideration of an alternative, and a replacement pathway has now been identified.
We are not there yet.
The next step is to secure PBS listing, reimbursement and supply arrangements before 1 November, alongside clear information for women and clinicians about what is changing and what they can access.
BCNA will keep working with government, clinicians and industry until that pathway is confirmed.
To every woman who shared her story and every clinician who stood beside them — thank you. Your voices helped move this forward.
Remember, if you have any questions, concerns or simply need someone to talk to, our Helpline Team is here for you Monday – Friday 9am-5pm AEST on 1800 500 258.
FYI: This injection is intramuscular NOT subcutaneous
Really exciting news Christina_BCNA - I can already see a few media items related to the announcement rolling out:
Pharmaceutical company bows to pressure, offers life-saving drug for free
PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend
NWhite1 FYI :)
arpie - I will reply to your post, but wanted to tag you here, so you can see we have been working hard in the background - that is for sure.
Thanks Daina, much appreciated - I'll check it out. 😊
Is there any new information available? Or a timeframe of when we might know more?
Hi NicoleUTM , thanks for checking in about this! At the moment, there’s no confirmed timeframe for when a decision will be made. BCNA is actively advocating on this issue and calling for the Government to reverse the PBS changes to Zoladex. BCNA is continuing to work closely with clinicians, government and other stakeholders to push for a solution, while supporting and listening to those affected. Keep the check ins coming and give us a ring on the Helpline at 1800 500 258 if there's anything we can support you with. To keep up with BCNA's latest Zolodex updates, you can visit: https://www.bcna.org.au/latest-news/bcna-news/update-on-access-to-zoladex-treatment
